Trastuzumab has been combined with cytotoxics, hormones, other monoclonal antibodies, such a pertuzumab and bevacizumab ... trastuzumab is the first monoclonal antibody to become available.

Goa is making significant strides in healthcare with initiatives like the Cancer Screening Abhiyan, which has benefited ...

It is recommended that women with early HER2+ breast cancer receive neoadjuvant subtype-specific systemic therapy, followed by surgery. 3 Paclitaxel plus trastuzumab, docetaxel/carboplatin ...

Trastuzumab is a monoclonal antibody targeted against the human epidermal growth factor receptor (HER) 2 tyrosine kinase receptor, which is overexpressed in approximately 25% of invasive breast ...

Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate (ADC) developed using Daiichi Sankyo's proprietary DXd ADC Technology. It represents the lead ADC in Daiichi Sankyo's oncology ...

In the article that accompanies this editorial, 16 the authors report clinical outcomes from the Japanese phase III JBCRG-M06/EMERALD trial, which compared first-line eribulin plus dual human ...

Antibody-drug conjugates (ADCs ... One of the most notable studies compared trastuzumab deruxtecan, a new ADC, with trastuzumab emtansine, the current standard treatment for HER2-positive ...

The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with ...

T-DM1 is an antibody-drug conjugate that combines trastuzumab and a chemotherapy drug called emtansine. When trastuzumab attaches to the HER2 receptor on cancer cells, it acts like a trojan horse ...